| Su1760 CLINICAL AND ENDOSCOPIC REMISSION AT 3 MONTHS AFTER ACUTE SEVERE ULCERATIVE COLITIS IS PREDICTIVE OF MAINTENANCE THERAPY OUTCOMES AT 12 MONTHS-RESULTS FROM PREDICT UC CFLW Suen, MC Choy, D Con, K Boyd, R Pena, K Burrell, O Rosella, ... Gastroenterology 166 (5), S-801, 2024 | | 2024 |
| 900 PREDICT UC: OPTIMISING INFLIXIMAB INDUCTION THERAPY FOR ACUTE SEVERE ULCERATIVE COLITIS-A RANDOMISED CONTROLLED TRIAL MC Choy, CFLW Suen, D Con, K Boyd, R Pena, K Burrell, O Rosella, ... Gastroenterology 166 (5), S-215, 2024 | | 2024 |
| Defining management strategies for acute severe ulcerative colitis using predictive models: a simulation-modeling study D Con, P De Cruz Intestinal Research, 2024 | | 2024 |
| Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply A Vasudevan, D Con, DR van Langenberg Alimentary Pharmacology & Therapeutics 59 (8), 1011-1011, 2024 | | 2024 |
| Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B D Con, S Tu, D Clayton-Chubb, JS Lubel, AJ Nicoll, R Sawhney, S Bloom Digestive Diseases and Sciences 69 (4), 1496-1506, 2024 | | 2024 |
| Safety and effectiveness of Janus kinase inhibitors in the management of inflammatory bowel disease following liver transplantation D Con, P Hilley, S Chin, C Corte, B Hafeez, A Testro, P De Cruz, M Choy, ... Journal of Crohn's and Colitis, jjae039, 2024 | 1 | 2024 |
| Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply A Vasudevan, D Con, DR van Langenberg Alimentary Pharmacology & Therapeutics 59 (6), 794-794, 2024 | | 2024 |
| Clinical trial: combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study) A Vasudevan, D Con, P De Cruz, MP Sparrow, AB Friedman, M Garg, ... Alimentary Pharmacology & Therapeutics 59 (4), 504-514, 2024 | 7 | 2024 |
| Assessing quality of magnetic resonance enterography and its impact on disease assessment of ileal Crohn’s disease A Bohra, DJ Connoley, D Con, JP Segal, O Niewiadomski, A Vasudevan, ... Intestinal Research 22 (2), 152-161, 2024 | 4 | 2024 |
| PREDICT UC: Optimising Infliximab Induction therapy for Acute Severe Ulcerative Colitis-A Randomised Controlled Trial M Choy, CFD Suen, L Wai, D Con, K Boyd, R Pena, K Burrell, O Rosella, ... JOURNAL OF CROHNS & COLITIS 18, I1600-I1600, 2024 | | 2024 |
| Clinical and endoscopic remission at 3 months after Acute Severe Ulcerative Colitis is predictive of maintenance therapy outcomes at 12 months-Results from PREDICT UC C Suen, L Wai, MC Choy, D Con, K Boyd, R Pena, K Burrell, O Rosella, ... JOURNAL OF CROHNS & COLITIS 18, I1738-I1738, 2024 | | 2024 |
| Monocyte distribution width differentiates bacterial gastroenteritis from Acute Severe Ulcerative Colitis in patients presenting with diarrhoea C Suen, L Wai, S Kaul, E Tan, D Con, M Taylor, J Wiid, C Hogan, M Choy, ... JOURNAL OF CROHNS & COLITIS 18, I833-I833, 2024 | | 2024 |
| P962 Clinical and endoscopic remission at 3 months after Acute Severe Ulcerative Colitis is predictive of maintenance therapy outcomes at 12 months-Results from PREDICT UC C Li Wai Suen, MC Choy, D Con, K Boyd, R Pena, K Burrell, O Rosella, ... Journal of Crohn's and Colitis 18 (Supplement_1), i1748-i1748, 2024 | | 2024 |
| P872 PREDICT UC: Optimising Infliximab induction therapy for acute severe ulcerative colitis–A randomised controlled trial M Choy, CFD Li Wai Suen, D Con, K Boyd, R Pena, K Burrell, O Rosella, ... Journal of Crohn's and Colitis 18 (Supplement_1), i1611-i1611, 2024 | 2 | 2024 |
| P404 Monocyte distribution width differentiates bacterial gastroenteritis from Acute Severe Ulcerative Colitis in patients presenting with diarrhoea C Li Wai Suen, S Kaul, E Tan, D Con, M Taylor, J Wiid, C Hogan, M Choy, ... Journal of Crohn's and Colitis 18 (Supplement_1), i841-i841, 2024 | | 2024 |
| Comparing first‐line infliximab and vedolizumab for ulcerative colitis—it depends on how you use the drug D Con, A Srinivasan Alimentary Pharmacology & Therapeutics 59 (1), 140-141, 2024 | 1 | 2024 |
| Serum interleukin-4 is elevated in clinical drug-induced liver injury MN Liu, M Au, M Bishara, T Worland, D Con, S Chew, A McNiece, ... Scandinavian Journal of Gastroenterology 58 (12), 1499-1504, 2023 | | 2023 |
| Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis P Hilley, D Con, MC Choy, A Srinivasan, P De Cruz JGH Open 7 (12), 1012-1015, 2023 | | 2023 |
| The Effect of Aspirin Use on Incident Hepatocellular Carcinoma—An Updated Systematic Review and Meta-Analysis J Abdelmalak, N Tan, D Con, G Eslick, A Majeed, W Kemp, SK Roberts Cancers 15 (13), 3518, 2023 | 3 | 2023 |
| Hepatitis C virus in people with serious mental illness: an analysis of the care cascade at a tertiary health service with a pilot ‘identify and treat’strategy M Braude, T Phan, D Con, I Woolley, S Sundram, D Clarke, A Dev, ... Internal Medicine Journal 53 (5), 700-708, 2023 | 1 | 2023 |
Peter GibsonMonash university在 monash.edu 的电子邮件经过验证
